Close menu




May 16th, 2024 | 08:00 CEST

Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

  • Biotechnology
  • Pharma
  • renewableenergies
Photo credits: pixabay.com

The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: SIEMENS ENERGY AG NA O.N. | DE000ENER6Y0 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Cardiol Therapeutics: Next top news in June?

    The Cardiol Therapeutics share price has more than doubled this year, making it one of the top performers in the biotech sector in 2024. It is currently trading at USD 2.18, and analysts see even more potential. The experts at Canaccord recommend buying the shares of the specialist in cardiovascular diseases with a price target of USD 6. New study data, due to be published at the beginning of June, could trigger the next share price jump. The Company confirmed the schedule again on Tuesday.

    Cardiol reported that the Phase II study to assess the effects of CardiolRx™ on myocardial regeneration in patients with acute myocarditis ("ARCHER") was the subject of a presentation at the World Congress on Acute Heart Failure 2024 in Lisbon. Carsten Tschöpe from the Berlin Institute of Health Research at Charité presented the baseline data of the first 50 patients randomized in the ARCHER study. From Cardiol's perspective, the cardiology community is very interested in the novel approaches for the treatment of acute myocarditis, for which there are currently no therapies approved by the regulatory authorities in Europe and the US. The Company also stated that patient recruitment is progressing rapidly.

    Cardiol CEO David Elsley stated: "We are pleased to report that the ARCHER study has now reached over 85% of its target enrollment. We anticipate that the results of the ARCHER study will contribute to a better understanding of the therapeutic potential of CardiolRx™ and complement our already advanced Phase II MAvERIC-Pilot study in patients with recurrent pericarditis." Cardiol has again announced top-line results for the Phase II MAvERIC-Pilot study for early June 2024.

    The fact that Cardiol's share price is not showing any weakness ahead of the important data is a positive signal.

    BioNTech: How analysts are reacting to the quarterly figures

    BioNTech shareholders have been waiting for a positive signal for some time. The stock is trading at USD 92, well below its all-time high of USD 390 from 2021. The recently published quarterly figures have also failed to give the share price any new impetus. Analysts are also cautious. Since last week, there have only been "Hold" recommendations.

    BioNTech did not meet Goldman Sachs' expectations with its latest quarterly figures. According to the analysts, sales and profits were lower than expected. They, therefore, reduced the price target to USD 90. UBS is currently the most optimistic, although the analysts' fair value of USD 101 also offers only manageable upside potential. The experts consider BioNTech's oncology pipeline to be attractive. However, research takes time, and the share price will only likely benefit from this in the longer term. Deutsche Bank's price target for BioNTech shares is USD 95, and Jefferies believes the share price could reach USD 100.

    Siemens Energy: Share price soon -50%?

    Bernstein Research caused a stir on Tuesday with a possible halving of the Siemens Energy share price. The analysts pointed to risks in the US. An election victory for Donald Trump could lead to noticeable cuts in the German company's US business in the medium term. The Republican presidential candidate recently announced at a fundraising event that he would strengthen the domestic oil industry if he won the election. According to this, the promotion of renewable energies is to be massively curtailed. This is also likely to apply to offshore wind energy. Siemens Gamesa is a major player in this segment. Bernstein Research, therefore, rates the Siemens Energy share as "Underperform". The target price is EUR 12. However, the bulls are not letting this unsettle them at the moment. Yesterday alone, the share gained more than 1% and reached a new high for the year of EUR 24.51.

    Incidentally, Goldman Sachs is Siemens Energy's biggest fan among analysts. After last week's quarterly figures, it raised its price target from EUR 27 to EUR 32.70 and confirmed its "Buy" recommendation. The majority of analysts are also positive.

    Siemens Energy will report on its performance in the third quarter in August.


    Siemens Energy seems to have recovered from the past year's problems. Currently, a reference to the potential negative effects of a Donald Trump election victory is not enough to interrupt the stock's momentum. The Cardiol Therapeutics share continues to demonstrate strength, and analysts see plenty of room for growth. A short-term price jump is not expected for BioNTech, even though the long-term prospects appear positive.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 16th, 2024 | 07:00 CEST

    Attention: Here we go! Hydrogen and uranium on the rise: Plug Power, Nel ASA, Kraken Energy and Siemens Energy in focus

    • Mining
    • Uranium
    • Hydrogen
    • renewableenergies
    • Energy

    It has finally happened! After months of sell-offs in hydrogen shares, there was a sigh of relief across the sector the day before yesterday. The reason: industry leader Plug Power received a government guarantee of USD 1.66 billion as backing for the construction of six-megawatt sites nationwide to create an initial hydrogen infrastructure. The Department of Energy (DOE) is thus demonstrating that the US is serious about investing in alternative energies. The decision boosted the entire energy sector, with uranium also continuing its recent upward trend. Where do the opportunities lie for investors?

    Read

    Commented by Juliane Zielonka on May 16th, 2024 | 06:45 CEST

    Saturn Oil + Gas, RWE, thyssenkrupp - Full speed ahead in energy and heavy industry

    • Mining
    • Oil
    • Gas
    • renewableenergies

    The oil and gas industry has evolved significantly thanks to technological developments. The Canadian energy company Saturn Oil & Gas has already completed four successful wells in southeast Missouri, USA, in the first quarter of 2024, with promising results. Further strategic investments, such as the acquisition of assets and financing commitments, strengthen Saturn Oil & Gas as an industry leader. RWE reports positive quarterly results. Despite lower earnings in the 'Flexible Generation' segment, the Company is optimistic due to the expansion of renewable energy projects. Thyssenkrupp reported stable results in the second quarter, although order intake and sales were down compared to the previous year. CEO Miguel López emphasizes the progress made in Marine Systems. Despite challenges, thyssenkrupp is sticking to its forecasts. Where is an investment worthwhile?

    Read

    Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

    Bayer, Defence Therapeutics, Novavax - Major events

    • Biotechnology
    • Pharma

    The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.

    Read